Dr. Martignetti on Next-Generation Sequencing in Fallopian Tube Cancer

John A. Martignetti, MD, PhD
Published: Monday, Sep 18, 2017



John A. Martignetti, MD, PhD, associate professor of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai, network director for the Laboratory for Translational Research at the Western Connecticut Health Network, discusses next-generation sequencing for patients with fallopian tube cancer.

Next-generation sequencing technology has changed what we can see, explains Martignetti. The level of detail is greatly increased, which has benefitted the treatment landscape of fallopian tube cancer and ovarian cancer.

Circulating tumor DNA can detect cancers earlier, can provide prognostic information, and even has potential for use in screening, states Martignetti.
 
SELECTED
LANGUAGE


John A. Martignetti, MD, PhD, associate professor of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai, network director for the Laboratory for Translational Research at the Western Connecticut Health Network, discusses next-generation sequencing for patients with fallopian tube cancer.

Next-generation sequencing technology has changed what we can see, explains Martignetti. The level of detail is greatly increased, which has benefitted the treatment landscape of fallopian tube cancer and ovarian cancer.

Circulating tumor DNA can detect cancers earlier, can provide prognostic information, and even has potential for use in screening, states Martignetti.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: A Nurses' Guide to Managing Adverse Events Associated with PARP InhibitorsJun 30, 20201.0
Community Practice Connections™: Evolutions in the Treatment and Management of Advanced Cervical Cancer: Leveraging the Immunosuppressive Microenvironment, Addressing Ongoing Clinical NeedsJun 30, 20201.5
Publication Bottom Border
Border Publication
x